Skip to main content
SpringerLink
Log in

Bei therapieschwieriger Epilepsie nicht verzagen

Neuere Medikamente können den therapeutischen Durchbruch bringen

  • Fortbildung
  • Published:
Pädiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© Prof. Dr. Klaus Schunk

Literatur

  1. Löscher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35(9):935-63

  2. Leonhardt G. Was können die neuen anfallssupprimierenden Medikamente? DNP. 2022;23(4):46-54

  3. BAnz AT 25.06.2021 B4

Download references

Author information

Authors and Affiliations

  1. Klinik f. Kinder- u. Jugendmed., Gemeinschaftsklinikum Mittelrhein, Koblenzer Str. 115-155, 56065, Koblenz, Germany

    Thomas Hoppen

Authors
  1. Thomas Hoppen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Hoppen.

Ethics declarations

Der Autor erklärt, dass bei Erstellung dieses Beitrags keine Interessenkonflikte bestanden.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoppen, T. Bei therapieschwieriger Epilepsie nicht verzagen. Pädiatrie 35, 42–43 (2023). https://doi.org/10.1007/s15014-022-4799-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15014-022-4799-1

Search

Navigation